Anne Phillips Buys Shares of Sagimet Biosciences

Anne Phillips recently acquired 39,567 shares of Sagimet Biosciences Inc. (NasdaqGM: SGMT) on June 12, 2026. This insider purchase reflects confidence in the company as its stock currently trades at $6.48.

Insider Buying and Selling at Sagimet Biosciences Inc.

Several insiders at Sagimet Biosciences, including Anne Phillips, purchased 39,567 shares each on June 12, 2026. Other insiders involved in similar transactions on the same day include Beth Seidenberg, Paul Hoelscher, Elizabeth Grammer, Jennifer Jarrett, and George Kemble. These transactions were not conducted under a prearranged trading plan.

Other Institutional Activity in Sagimet Biosciences

Vanguard Capital Management LLC initiated a position in Sagimet Biosciences, acquiring 1,098,919 shares valued at approximately $5.74 million. Marshall Wace, LLP increased its holdings by 185,807 shares to a total of 966,253 shares, worth about $5.04 million. Meanwhile, Affinity Asset Advisors, LLC reduced its stake by 280,225 shares, ending with 868,020 shares valued at roughly $4.54 million. Millennium Management LLC also boosted its position by 275,356 shares, holding 862,303 shares valued at approximately $4.51 million.

Sagimet Biosciences Stock Snapshot

Shares of Sagimet Biosciences Inc. (NasdaqGM: SGMT) are trading at $6.48. The company has a market capitalization of about $399.5 million and does not currently have a meaningful P/E ratio due to its unprofitability. The stock's 52-week range is between $4.50 and $11.41. It has a 50-day moving average of $6.82 and a 200-day moving average of $6.56. The company's liquidity ratios are strong, with a current ratio of 20.34 and a quick ratio of 19.74, and it has a low debt-to-equity ratio of 0.038.

Analysts Set New Price Targets

Analysts maintain a favorable outlook on Sagimet Biosciences. On May 19, 2026, Citizens maintained a 'buy' rating with a $12.00 price target. Canaccord Genuity also reiterated its 'buy' rating with a $49.00 target on May 4, 2026. Guggenheim continues to support the stock with a 'buy' rating and a $25.00 target as of April 29, 2026. Overall, the consensus among analysts suggests a mean price target of $26.20, based on 10 different opinions.

About Sagimet Biosciences

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California. It specializes in developing novel therapeutics known as fatty acid synthase (FASN) inhibitors. These are used to treat diseases stemming from dysfunctional metabolic and fibrotic pathways. Their lead drug candidate, Denifanstat, is being developed for conditions such as metabolic dysfunction-associated steatohepatitis and certain types of cancer. The company, led by CEO David A. Happel, has a small team of 16 employees.

Bottom Line

Anne Phillips' insider purchase of Sagimet Biosciences shares is a positive signal of confidence. The company is working on innovative treatments, though it remains unprofitable. Analysts seem optimistic, with a consensus price target significantly higher than the current trading price. However, as this is based on past transactions, it might not reflect the most current position.